Share this
Structure Therapeutics – $185.3 Million IPO
February 9, 2023
FDORA’s Changes to the FDA Accelerated Approval Program
Cooley Alert • January 31, 2023
FDA Doubles Down on Its Pre-Catalyst Stance on Orphan Drug Exclusivity
Cooley Alert • January 27, 2023
Angion and Elicio Therapeutics Enter Into Definitive Merger Agreement
January 19, 2023
CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion
January 9, 2023
Tmunity Therapeutics to Sell to Kite
December 22, 2022
Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion
December 12, 2022
Apollo Endosurgery to Be Acquired by Boston Scientific
December 2, 2022
Neogene Therapeutics to Sell to AstraZeneca
November 30, 2022
Oyster Point Pharma to Be Acquired by Viatris
November 9, 2022
Vaxcyte – $690 Million Public Offering
October 31, 2022
Oculis and European Biotech Acquisition Corp. Announce Business Combination Agreement
October 25, 2022
Opthea Secures $170 Million Financing and $90 Million Private Placement
Proceeds to advance phase 3 clinical trials and pre-commercialization activities of lead drug candidate OPT-302 • August 23, 2022
Poseida Therapeutics Enters Strategic Collaboration and License Agreement With Roche
Poseida to receive $110 million upfront, with overall potential deal value of up to $6 billion • August 5, 2022
FDA Unveils Considerations for Rescinding Breakthrough Therapy Designation
Cooley Alert • August 2, 2022
Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals
July 13, 2022
Cytokinetics – $450 Million Convertible Senior Notes Offering
July 8, 2022
Sixth Street Invests in Blueprint Medicines
July 6, 2022
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Cell Therapy Programs
June 9, 2022
Liquid Biopsy Technology: FDA’s Latest Guidance Supports Several Uses of ctDNA in Clinical Trials, but Not (yet) as Surrogate Clinical Endpoint
Cooley Alert • June 8, 2022
Turning Point Therapeutics to Sell to Bristol Myers Squibb for $4.1 Billion
June 3, 2022
FDA Releases Draft Guidance on Development of Genome Editing and CAR T Therapies
Cooley Alert • April 14, 2022
DOJ Previews Enforcement Policies Aimed at Clinical Trial Fraud
Cooley Alert • December 20, 2021
Arena Pharmaceuticals Agrees to Sell to Pfizer for $6.7 Billion
December 15, 2021
Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II
Transaction to accelerate company’s mission of bringing cost-effective biosimilars to patients in all major markets around the globe • December 9, 2021
Baylis Medical Agrees to Sell to Boston Scientific for $1.75 Billion
October 21, 2021
Warby Parker – Direct Listing
First public benefit corporation to trade on public markets through direct listing • October 13, 2021
ZOLL Medical Agrees to Acquire Itamar Medical for $538 Million
September 21, 2021
Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion
August 5, 2021
Lyell Immunopharma – $425 Million IPO
Third largest biotech IPO in history • July 20, 2021
What to Watch as EU Clinical Trial Compliance Changes
Law360 • July 19, 2021
The Honest Company – $475 Million IPO
May 10, 2021
Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion
March 16, 2021
Horizon Therapeutics to Acquire Viela Bio to Grow Rare Disease Medicine Portfolio
February 5, 2021
Celularity to Go Public Through SPAC Merger
January 13, 2021
VelosBio Agrees to Sell to Merck for $2.75 Billion
November 9, 2020
Opthea – $128 Million IPO
Largest IPO by a development-stage Australian life sciences company • November 3, 2020
Neurocrine Partners With Takeda to Address Psychiatric Disorders
June 29, 2020
Orca Bio Raises $192 Million Series D to Transform Allogeneic Cell Therapy
June 23, 2020
CARES Act: What You Need to Know
Cooley Alert • March 29, 2020
Forty Seven Agrees to Sell to Gilead for $4.9 Billion
March 2, 2020
Synthorx Agrees to Sell to Sanofi for $2.5 Billion
December 9, 2019
Cooley Advises on Follow-On Offerings for Reata + argenx
Transactions total more than $1 billion • December 5, 2019
Avidity Biosciences Closes $100 Million Series C
November 13, 2019
ArTara Agrees to Combine With Proteon
Transaction to create Nasdaq-listed rare and specialty disease therapeutic company • September 27, 2019
Gossamer Bio – $317 Million IPO
One of the largest healthcare IPOs of the last 20 years • February 21, 2019
Taiwan Liposome Company Completes US IPO
January 3, 2019
Arena Pharmaceuticals Enters $1.2 Billion Agreement With United Therapeutics
November 30, 2018
Liquidia – $53 Million IPO
August 21, 2018
Agilis Biotherapeutics Sells to PTC for $200 Million
Combination expands gene therapy programs for treatment of rare diseases • July 30, 2018
Scholar Rock – $86 Million IPO
June 18, 2018
ASLAN Pharmaceuticals – $42 Million IPO
First Taipei Exchange-listed company to go public in US • June 8, 2018
Sucampo Sells to Mallinckrodt for $1.2 Billion
December 27, 2017
Crown Bioscience Enters Merger Agreement With JSR Corporation
December 22, 2017
OrthoPediatrics – $60 Million IPO
December 21, 2017
Cell Design Labs Sells to Gilead
December 8, 2017
ERYTECH – $144 Million IPO
November 22, 2017
HBM Healthcare Invests in Harmony Biosciences’ $270 Million Equity Financing
October 30, 2017
Cooley Advises on Nightstar + NuCana IPOs
Pair of transactions highlight strength across life sciences sector public offerings • October 10, 2017
Jazz Pharmaceuticals Strikes Strategic Collaboration and Option Agreement with ImmunoGen
Deal diversifies + strengthens Jazz's hematology, oncology portfolio • September 12, 2017
Zealand Pharma – $89 Million IPO
August 25, 2017
SoftBank Vision Fund Leads $1.1 Billion Financing of Roivant Sciences
August 14, 2017
SELLAS Life Sciences Group to Merge with Galena Biopharma
August 11, 2017
Ovid – $75 Million IPO
June 13, 2017
Cooley Advises on Series of Life Sciences IPOs
Zymeworks, Verona, UroGen and Biohaven IPOs highlight core strengths across the sector • May 30, 2017
ZIOPHARM Oncology – $50 Million Offering
May 17, 2017
Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out
May 10, 2017
Audentes – $86 Million Shelf-Takedown Offering
April 27, 2017
Tocagen – $98 Million IPO
April 20, 2017
FibroGen – $120 Million Shelf Takedown
April 19, 2017
Sucampo Acquires Vtesse
April 12, 2017
Calithera Biosciences – $80 Million Shelf-Takedown Offering
April 7, 2017
Valeritas – $53 Million IPO
Vital Therapies – $40 Million Follow-on Offering
March 29, 2017
Aurinia – $173 Million Offering
March 23, 2017
Prothena – $155 Million Shelf-Takedown Offering
Anthera – $15 Million Shelf-Takedown Offering
March 22, 2017
Kite Pharma – $410 Million Shelf‑Takedown Offering
Dermira – $194 Million Shelf-Takedown
March 10, 2017
Global Blood Therapeutics – $144 Million Shelf‑Takedown
March 8, 2017
Sierra Oncology – $29.5 Million Shelf-Takedown
February 23, 2017
Rigel – $46 Million Shelf-Takedown
February 17, 2017
ObsEva – $97 Million IPO
February 16, 2017
ZELTIQ Aesthetics to Sell to Allergan for $2.5 Billion
February 14, 2017
Mirati – $69 Million Shelf-Takedown
January 12, 2017
NantHealth – $107 Million Notes Offering
January 11, 2017
Aurinia – $28.75 Million Offering
January 6, 2017
Clearside – $36 Million Public Offering
January 3, 2017
Xencor – $127 Million Shelf-Takedown
December 8, 2016
TRACON – $17 Million Shelf-Takedown
December 6, 2016
Aclaris Therapeutics – $105 Million Follow-On Offering
November 30, 2016
Invitae – $51 Million Follow-On
Flexion – $70 Million Shelf-Takedown
November 29, 2016
Ascendis Pharma – $136 Million Follow-On
November 3, 2016
Myovant Raises $218 Million in Largest Biotech IPO of Year
October 31, 2016
Tabula Rasa – $59 Million IPO
October 25, 2016
Cidara – $28 Million Follow-On Offering
October 21, 2016
Novan – $52 Million IPO
October 14, 2016
Aquinox – $75 Million Public Offering
October 13, 2016
Charles River Acquires Agilux
October 11, 2016
Catabasis – Underwritten Registered Offering
October 7, 2016
AveXis – $169 Million Follow-On Offering
September 21, 2016
BioMarin – $720 Million Follow-On
September 19, 2016
Xenon Pharmaceuticals – $34.5 Million Follow-On
September 16, 2016
Horizon Pharma to Buy Raptor Pharmaceutical for $800 Million
September 15, 2016
Sophiris Bio – $30 Million Follow-On
September 13, 2016
Eiger – $20 Million Shelf-Takedown
September 1, 2016
Recro Pharma – $15 Million Follow-On
August 30, 2016
Protagonist Therapeutics – $90 Million IPO
Advaxis – $30 Million Registered Direct Offering
Acadia – $230 Million Follow-On
August 25, 2016
Medivation Agrees to Sell to Pfizer for $14 Billion
August 23, 2016
Gemphire Therapeutics – $30 Million IPO
August 22, 2016
Inotek Pharmaceuticals – $50 Million Follow-On
August 18, 2016
Audentes Therapeutics – $85 Million IPO
July 29, 2016
Syros IPO – $58 Million
July 26, 2016
Selecta Biosciences – $74 Million IPO
July 25, 2016
Flexion – $77 Million Follow-On Offering
July 7, 2016
Minerva – $58 Million Follow-On Offering
Dermira – $145 Million Follow-On Offering
June 23, 2016
Clearside IPO – $50 Million
June 21, 2016
NantHealth IPO – $97 Million
June 13, 2016
Merus IPO – $61 Million
June 1, 2016
Jazz Pharmaceuticals to Acquire Celator for $1.5 Billion
Oncobiologics – $40 Million IPO and Private Placement
May 19, 2016
Senseonics Holdings, Inc. – $49 Million IPO
April 13, 2016
WAVE Life Sciences – IPO
December 7, 2015
Voyager Therapeutics – IPO
November 19, 2015
Cardioxyl Sells to Bristol-Myers Squibb for up to $2 Billion
November 5, 2015
Strongbridge Biopharma – IPO
October 27, 2015
Aclaris Therapeutics – IPO
October 20, 2015
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015
Scioderm Sells to Amicus Therapeutics for up to $947 Million
October 2, 2015
Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin
August 24, 2015
NantKwest – $238 Million IPO
August 14, 2015
ProNAi – $158 Million IPO
August 7, 2015
Chiasma Completes $117 Million IPO
July 31, 2015
Celyad Completes $100 Million IPO
July 27, 2015
Catabasis Completes IPO
July 20, 2015
Axovant Completes $362 Million IPO
June 16, 2015
HTG Completes its Initial Public Offering
May 20, 2015
Aduro Completes $137 Million Initial Public Offering
April 30, 2015
KemPharm Completes its Initial Public Offering
April 28, 2015
Cidara Completes its Initial Public Offering
April 24, 2015
Horizon Pharma to Acquire Hyperion Therapeutics for $1.1 Billion
March 31, 2015
Auspex Pharma to be Acquired by Teva for $3.5 Billion
Cooley Simultaneously Handles Billion Dollar Deals
Daily Journal, The Recorder, Bloomberg, Law360, Reuters, RTE News and Street Insider • March 30, 2015
Invitae Completes $117 Million Initial Public Offering
February 25, 2015
Inotek Pharmaceuticals – $40 Million IPO
February 23, 2015
TRACON Pharmaceuticals Completes Initial Public Offering
February 13, 2015
Bellicum Completes $160 Million Initial Public Offering
Nexvet Biopharma Closes Initial Public Offering
Ascendis Pharma Closes $124 Million Initial Public Offering
NewLink Will License Ebola Vaccine to Merck
December 9, 2014
Ionis Pharmaceuticals Completes Rule 144A Offering of $500 Million of Convertible Senior Notes
December 2, 2014
Xenon Pharmaceuticals Completes its Initial Public Offering
November 21, 2014
Atara Completes its Initial Public Offering
November 6, 2014
DBV Technologies Completes Concurrent Public Offerings
Vascular Biogenics Prices its Initial Public Offering
November 5, 2014
Sientra Completes Initial Public Offering
November 3, 2014
NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research and Development
October 22, 2014
Vitae Pharmaceuticals Completes Initial Public Offering
October 10, 2014
Cooley Advises Underwriters on T2 Biosystems IPO
August 22, 2014
Cooley Advises Underwriters on Otonomy IPO
August 19, 2014
Cooley Advises Underwriters on Immune Design IPO
August 11, 2014
Cooley Advises GlobeImmune on Initial Public Offering
August 7, 2014
Cooley Advises Intersect ENT on $63 Million Initial Public Offering
July 31, 2014
Cooley Advises Underwriters on Minerva Neurosciences IPO
July 11, 2014
Cooley Advises Kite Pharma on $146 Million Initial Public Offering
July 1, 2014
Cooley Advises ProteinSimple in $300 Million Sale to Techne Corporation
June 20, 2014
Cooley Advises Alder Biopharmaceuticals on Initial Public Offering
May 14, 2014
Cooley Advises Adamas Pharmaceuticals on Initial Public Offering
April 30, 2014
Cooley Advises Underwriters on TriVascular IPO
April 23, 2014
Cooley Advises Underwriters on Vital Therapies Initial Public Offering
Cooley Advises Versartis on its $145 Million IPO
March 31, 2014
Cooley Advises Horizon Pharma on $660 Million Acquisition of Vidara Therapeutics
March 27, 2014
Cooley Advises Underwriters on Amedica IPO
March 4, 2014
Cooley Advises Eagle on Initial Public Offering
February 26, 2014
Cooley Advises Flexion on Initial Public Offering
Cooley Advises Auspex on its Initial Public Offering
February 24, 2014
Cooley Advises Underwriters on Egalet Corporation IPO
February 21, 2014
Cooley Advises Underwriters on Genocea Biosciences IPO
Cooley Advises Underwriters on Eleven Biotherapeutics IPO
February 14, 2014
Cooley Advises Revance on its Initial Public Offering
February 13, 2014
Cooley Advises Trevena on its Initial Public Offering
February 11, 2014
Cooley Advises Celladon on its Initial Public Offering
Cooley Advises Cara Therapeutics on its Initial Public Offering
February 6, 2014
Cooley Advises Jazz Pharmaceuticals in Acquisition of ADX-N05
January 23, 2014
Cooley Advises on First US IPO of 2014 for GlycoMimetics
Cooley Advises Underwriters on TetraLogic Initial Public Offering
December 26, 2013
Cooley Advises Xencor on its Initial Public Offering
December 10, 2013
Cooley Advises Apollo Endosurgery in Agreement to Acquire Obesity Intervention Division of Allergan
October 29, 2013
FDA Issues Final Guidance Regarding Mobile Medical Applications
Cooley Alert • September 25, 2013
Cooley Advises Underwriters on Five Prime Therapeutics IPO
September 23, 2013
Cooley Advises Underwriters on Onconova Therapeutics IPO
August 8, 2013
Cooley Represents AcelRx Pharmaceuticals in Public Offering
July 25, 2013
Cooley Represents IDEV Technologies in its Acquisition by Abbott Labs
July 17, 2013
Cooley Launches New Health Care and Life Sciences Regulatory Blog –TheBeat @ CooleyHealth
US Supreme Court Allows Antitrust Suits Against “Reverse Payment” Settlements of Patent Litigation and Orders Third Circuit to Apply the New Standard; EU Also Pursues Enforcement
Cooley Alert • June 25, 2013
Cooley Advises Underwriters on Epizyme, Inc. Initial Public Offering
June 14, 2013
Cooley Advises Portola Pharmaceuticals on its $140 Million IPO
May 29, 2013
Cooley Advises Ambit on its Initial Public Offering
May 21, 2013
Cooley Advises Underwriters on Receptos, Inc. Initial Public Offering
May 20, 2013
Cooley Advises Insys Therapeutics on its IPO
May 9, 2013
Jawbone Acquisition of Body Media
April 30, 2013
Cooley Advises Jazz Pharmaceuticals in $314.4 Million Offering
March 8, 2013
Cooley Represents BioMarin in $10 Million Acquisition of Zacharon
January 9, 2013
Supreme Court Agrees to Review Antitrust Challenges to "Reverse Payment" Patent Litigation Settlement Agreements
Cooley Alert • December 14, 2012
Cooley Closes 2nd Life Sciences Deal In 2 Days (Law360)
October 18, 2012
Draft Biosimilars Guidances Released by Food and Drug Administration
Cooley Alert • February 16, 2012
Healthcare Reform Law Will Provide Cash Grants and Tax Credits for Qualifying Life Sciences Companies
Cooley Alert • March 31, 2010